Key Takeaways Eli Lilly's Zepbound has been approved by the Food and Drug Administration (FDA) as a treatment for adults with sleep apnea and obesity, the drugmaker said after the bell Friday.Trials of the Lilly drug found that it helped reduce the number of breathing disruptions in an average night of sleep.

The US FDA approved Eli Lilly's Zepbound as the first ever medication for obstructive sleep apnea for patients who also have obesity

Zepbound, a popular weight loss drug, has become the first FDA-approved prescription medication to treat obstructive sleep apnea.

The Food and Drug Administration (FDA) approved a weight-loss drug to help sleep apnea, becoming the first drug to treat the disorder affecting millions of Americans. On Friday, the federal agency green-lighted Eli Lilly’s Zepbound drug for the use,

Zepbound is the first prescription drug approved specifically to treat the common condition. The Food and Drug Administration on Friday approved the weight loss drug Zepbound to treat obstructive sleep apnea. It is the first prescription medication approved to treat the common sleep disorder.

The mega-blockbuster weight loss GLP-1 drug is now also approved to treat obstructive sleep apnea in adults with obesity, in combination with diet and exercise.

The U.S. Food and Drug Administration (FDA) has approved the first prescription medication specifically for treating o

Zepbound is Eli Lilly’s weight loss drug. Now, it is also a drug to treat obstructive sleep apnea (OSA).The U.S. Food and Drug Administration has appro

The US Food and Drug Administration on Friday approved the first prescription medicine for obstructive sleep apnea: the weight-loss drug Zepbound.

The FDA said studies have shown that by aiding weight loss, Zepbound improves sleep apnea symptoms in some patients.

In the trial that Lilly, the drug's manufacturer, submitted in April to the FDA, scientists reported that the drug helped people who were overweight or obese with sleep apnea redu